Results 221 to 230 of about 3,896,424 (394)
Prediction of repurposed drugs for treating lung injury in COVID-19
Bing He, Lana X. Garmire
openalex +1 more source
Pentoxifylline dose finding trial in preterm neonates with suspected late onset sepsis (PTX‐trial)
Aim The aim of this study (PTX‐trial) is to determine the optimal dose of pentoxifylline (PTX) in preterm neonates (gestational age < 30 weeks) with (suspected) late onset sepsis (LONS). Methods The PTX‐trial is a prospective multicentre open‐label sequential dose‐optimization study with an adapted continual reassessment method.
Serife Kurul +7 more
wiley +1 more source
Drug Repurposing in Veterinary Oncology: Myth or Reality? [PDF]
Ciccarelli S +3 more
europepmc +1 more source
Repurposing of drugs for Covid-19: a systematic review and meta-analysis [PDF]
Pinky Kotecha +7 more
openalex +1 more source
Low‐intervention clinical trials in Spain: Do they progress?
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza +4 more
wiley +1 more source
Correction: Editorial: Opportunities and challenges in drug repurposing. [PDF]
Camps I +3 more
europepmc +1 more source
Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra +8 more
wiley +1 more source
AΙ-Driven Drug Repurposing: Applications and Challenges. [PDF]
Keramida P +5 more
europepmc +1 more source
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola +5 more
wiley +1 more source

